Please login to the form below

Not currently logged in
Email:
Password:

Cushing's disease

This page shows the latest Cushing's disease news and features for those working in and with pharma, biotech and healthcare.

Novartis' acromegaly therapy cleared by FDA

Novartis' acromegaly therapy cleared by FDA

It leads to an increase in bone size, particularly those in the hands, feet and face, alongside other complications such as diabetes, arthritis, kidney disease and cancer. ... A short-acting formulation of Signifor that requires twice-daily dosing is

Latest news

  • Novartis gets EU nod for rare disease drug Signifor Novartis gets EU nod for rare disease drug Signifor

    Signifor (pasireotide) was first approved in Europe in 2012 as a twice-daily subcutaneous injection for Cushing's disease, but the new depot formulation - called Signifor LAR - requires just one intramuscular ... It is also testing the new formulation

  • Novartis plans filings for acromegaly candidate Novartis plans filings for acromegaly candidate

    A twice-daily formulation of Signifor (pasireotide) is already on the market for the treatment of Cushing's disease, but the latest study assessed a once-monthly intramuscular formulation - called Signifor ... The company has already filed for approval

  • Novartis cancer chief Hoppenot leaves for top job at Incyte Novartis cancer chief Hoppenot leaves for top job at Incyte

    During his time at the helm of Novartis' cancer division Hoppenot presided over the launch of two new cancer therapies, Jakavi for myelofibrosis in 2011 and Signifor (pasireotide) for Cushing's ... disease in 2012, while rolling out new indications for

  • Novartis provides multimedia support to Rare Diseases Day Novartis provides multimedia support to Rare Diseases Day

    Novartis has collaborated with rare diseases organisation Eurordis to help raise public awareness of rare disease. ... The initiative includes fact sheets, infographics and advice on diseases such as  Cushing's disease, gastrointestinal stromal tumor

  • Year-end FDA approvals for Novartis, GSK drugs Year-end FDA approvals for Novartis, GSK drugs

    Year-end FDA approvals for Novartis, GSK drugs. Agency gives go-ahead to Cushing’ s disease treatment Signifor and raxibacumab for inhalational anthrax. ... patients with Cushing's disease treated with Signifor; and focused safety monitoring for

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    Jakavi (rare bone marrow disorder); Signifor (Cushing's disease) plus 16 products in 24 pivotal trials. ... Well-known brands include:. • Pain: Excedrin (Novartis), Beecham's headache powder and Panadol (GSK). •

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics